C

China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570

Watchlist Manager
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Watchlist
Price: 2.08 HKD 1.96% Market Closed
Market Cap: 10.5B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one China Traditional Chinese Medicine Holdings Co Ltd stock under the Base Case scenario is 2.93 HKD. Compared to the current market price of 2.08 HKD, China Traditional Chinese Medicine Holdings Co Ltd is Undervalued by 29%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2.93 HKD
Undervaluation 29%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

0.6
P/S
P/S
Price to Sales
0.6
vs History
92
vs Industry
81
Median 3Y
1
Median 5Y
1
Industry
2.4
Forward
0.6
More Details
180.4
P/E
P/E
Price to Earnings
180.4
vs History
1
vs Industry
38
Median 3Y
17.7
Median 5Y
11.8
Industry
20.3
Forward
11.3
More Details
4.1
P/OCF
P/OCF
Price to OCF
4.1
vs History
92
vs Industry
49
Median 3Y
15.3
Median 5Y
14.3
Industry
15.6
More Details
77.1
P/FCFE
P/FCFE
Price to FCFE
77.1
vs History
1
vs Industry
16
Median 3Y
11.8
Median 5Y
-9.9
Industry
23.1
More Details
0.5
P/B
P/B
Price to Book Value
0.5
vs History
92
vs Industry
76
Median 3Y
0.8
Median 5Y
0.9
Industry
2
More Details
0.4
EV/S
EV/S
Enterprise Value to Sales
0.4
vs History
92
vs Industry
87
Median 3Y
0.8
Median 5Y
0.8
Industry
2.5
Forward
0.4
More Details
0.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
0.8
vs History
90
vs Industry
85
Median 3Y
1.5
Median 5Y
1.4
Industry
4.8
More Details
7.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.9
vs History
22
vs Industry
39
Median 3Y
7.3
Median 5Y
6
Industry
12.5
Forward
3.1
More Details
7.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.9
vs History
41
vs Industry
42
Median 3Y
9.8
Median 5Y
7.1
Industry
15.7
Forward
5.6
More Details
2.7
EV/OCF
EV/OCF
Enterprise Value to OCF
2.7
vs History
92
vs Industry
51
Median 3Y
12.4
Median 5Y
10.8
Industry
14.1
More Details
3.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
3.3
vs History
63
vs Industry
38
Median 3Y
8.9
Median 5Y
15.4
Industry
17.6
More Details
0.3
EV/IC
EV/IC
Enterprise Value to IC
0.3
vs History
90
vs Industry
80
Median 3Y
0.5
Median 5Y
0.5
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
China Traditional Chinese Medicine Holdings Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
10.5B HKD 0.6 180.4 7.9 7.9
US
Eli Lilly and Co
NYSE:LLY
736.1B USD 15 66.3 35.6 38.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
378.4B USD 4.2 17.4 12.7 16.6
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.6 13 14.7
CH
Roche Holding AG
SIX:ROG
211.7B CHF 3.5 25.6 9.6 11.2
CH
Novartis AG
SIX:NOVN
180B CHF 4.1 17 10 13.4
UK
AstraZeneca PLC
LSE:AZN
162.9B GBP 4 28 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
200B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.6B USD 2.1 16.4 7.1 10
P/E Multiple
Earnings Growth PEG
HK
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Average P/E: 42.5
180.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.3
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.4
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.6
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.6
32%
0.8
CH
Novartis AG
SIX:NOVN
17
17%
1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.4
29%
0.6

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.